About Charles River Laboratories International (NYSE:CRL)
Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company's clients' manufacturing activities.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Life Sciences Tools & Services
- Symbol: NYSE:CRL
- CUSIP: 15986410
- Web: www.criver.com
- Market Cap: $5.48138 billion
- Outstanding Shares: 47,593,000
- 50 Day Moving Avg: $109.43
- 200 Day Moving Avg: $99.39
- 52 Week Range: $67.20 - $115.96
Sales & Book Value:
- Trailing P/E Ratio: 30.28
- Foreward P/E Ratio: 20.41
- P/E Growth: 2.08
- Annual Revenue: $1.81 billion
- Price / Sales: 3.02
- Book Value: $20.25 per share
- Price / Book: 5.67
- EBITDA: $435.89 million
- Net Margins: 10.13%
- Return on Equity: 27.02%
- Return on Assets: 8.84%
- Debt-to-Equity Ratio: 1.16%
- Current Ratio: 1.74%
- Quick Ratio: 1.49%
- Average Volume: 361,717 shs.
- Beta: 0.96
- Short Ratio: 5.44
Frequently Asked Questions for Charles River Laboratories International (NYSE:CRL)
What is Charles River Laboratories International's stock symbol?
Charles River Laboratories International trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."
How will Charles River Laboratories International's stock buyback program work?
Charles River Laboratories International declared that its board has authorized a stock buyback plan on Sunday, June 4th 2017, which allows the company to buyback $150,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Stock buyback plans are often a sign that the company's board of directors believes its stock is undervalued.
How were Charles River Laboratories International's earnings last quarter?
Charles River Laboratories International, Inc. (NYSE:CRL) announced its quarterly earnings data on Wednesday, August, 9th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.22 by $0.07. The company had revenue of $469.13 million for the quarter, compared to analyst estimates of $458.25 million. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The company's revenue was up 8.1% compared to the same quarter last year. During the same period in the previous year, the company earned $1.20 earnings per share. View Charles River Laboratories International's Earnings History.
When will Charles River Laboratories International make its next earnings announcement?
What guidance has Charles River Laboratories International issued on next quarter's earnings?
Charles River Laboratories International issued an update on its FY17 earnings guidance on Wednesday, August, 9th. The company provided earnings per share guidance of $5.00-5.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.10. The company issued revenue guidance of $1.82-1.85 billion (+8.5-10%), compared to the consensus revenue estimate of $1.83 billion.
Where is Charles River Laboratories International's stock going? Where will Charles River Laboratories International's stock price be in 2017?
9 brokerages have issued twelve-month price targets for Charles River Laboratories International's shares. Their predictions range from $77.00 to $130.00. On average, they anticipate Charles River Laboratories International's share price to reach $103.17 in the next year. View Analyst Ratings for Charles River Laboratories International.
What are analysts saying about Charles River Laboratories International stock?
Here are some recent quotes from research analysts about Charles River Laboratories International stock:
- 1. According to Zacks Investment Research, "Charles River Laboratories is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. Charles River is the global leader in providing the animal research models required in research and development for new drugs, devices and therapies and has been in this business for more than 50 years. " (8/11/2017)
- 2. UBS AG analysts commented, "CRL reported 4Q16 results with reported revenue of $467m, above both our estimate of $442m and consensus estimates of $441m. Adj. EPS of $1.21 was above both ours and consensus estimates of $1.11. Management guided to 7.5% ' 9% revenue growth (7% ' 8.5% org.) and adj. EPS of $5.00 - $5.10 for FY17. For 1Q17, reported revenue growth is expected in the mid-20% and adj. EPS growth of mid- to high-teens' Our Sell rating is based on the following: 1) We are becoming more selective in our CRO universe and CRL is primarily exposed to early development markets which we think are most at risk should biopharma markets slow. 2) We estimate that street forecasts for 2017 are too high and think CRL's multiple could revert to its mean should estimates need to come down as we anticipate. 3) We estimate that CRL is most at risk in our universe should interest rates begin to rise." (2/15/2017)
- 3. Jefferies Group LLC analysts commented, "4Q results far outpaced consensus revenue/EPS driven by strength across the 3 segments. Guidance bracketed consensus, lower than us (as expected). We point to margin expansion (with continued price) and capital deployment as upside sources. Strong Discovery and Early Development demand (see our research pointing to funding shifts to Early Dev) should support high single digit organic growth." (2/15/2017)
Who are some of Charles River Laboratories International's key competitors?
Some companies that are related to Charles River Laboratories International include Alnylam Pharmaceuticals (ALNY), Seattle Genetics (SGEN), Ionis Pharmaceuticals (IONS), Alkermes PLC (ALKS), Qiagen N.V. (QGEN), ICON PLC (ICLR), Exact Sciences Corporation (EXAS), INC Research Holdings (INCR), United Therapeutics Corporation (UTHR), PRA Health Sciences (PRAH), Galapagos NV (GLPG), Bio-Techne Corp (TECH), Puma Biotechnology (PBYI), PAREXEL International Corporation (PRXL), ACADIA Pharmaceuticals (ACAD), FibroGen (FGEN), Nektar Therapeutics (NKTR) and WuXi PharmaTech (Cayman) (WX).
Who are Charles River Laboratories International's key executives?
Charles River Laboratories International's management team includes the folowing people:
- James C. Foster, Chairman of the Board, President, Chief Executive Officer
- David R. Smith, Chief Financial Officer, Corporate Executive Vice President
- David P. Johst, Corporate Executive Vice President - Human Resources, Chief Administrative Officer, General Counsel
- William D. Barbo, Corporate Executive Vice President and Chief Commercial Officer
- Davide A. Molho, Corporate Executive Vice President & President, Global Research Models & Services, Safety Assessment and Biologics
- Michael Gunnar Knell, Corporate Senior Vice President, Chief Accounting Officer
- George M. Milne Jr., Ph.D., Lead Independent Director
- Martin Mackay Ph.D., Director
- Robert J. Bertolini, Independent Director
- Stephen D. Chubb, Independent Director
Who owns Charles River Laboratories International stock?
Charles River Laboratories International's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.95%), Personal Capital Advisors Corp (0.25%), APG Asset Management N.V. (0.21%), Nationwide Fund Advisors (0.17%), Mutual of America Capital Management LLC (0.08%) and Shell Asset Management Co. (0.08%). Company insiders that own Charles River Laboratories International stock include C Richard Reese, David P Johst, David Ross Smith, Davide Molho, George M Milne Jr, George Massaro, James C Foster, John J Crowley, Nancy Gillett, Richard F Wallman, Robert J Bertolini, Stephen D Chubb, Thomas F Ackerman and William D Barbo. View Institutional Ownership Trends for Charles River Laboratories International.
Who sold Charles River Laboratories International stock? Who is selling Charles River Laboratories International stock?
Charles River Laboratories International's stock was sold by a variety of institutional investors in the last quarter, including Personal Capital Advisors Corp, Fisher Asset Management LLC, State Treasurer State of Michigan and Nationwide Fund Advisors. Company insiders that have sold Charles River Laboratories International stock in the last year include C Richard Reese, David P Johst, David Ross Smith, Davide Molho, George Massaro, James C Foster, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Insider Buying and Selling for Charles River Laboratories International.
Who bought Charles River Laboratories International stock? Who is buying Charles River Laboratories International stock?
Charles River Laboratories International's stock was acquired by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Shell Asset Management Co., Meeder Asset Management Inc., Fox Run Management L.L.C., Moloney Securities Asset Management LLC, CAPROCK Group Inc. and Mutual of America Capital Management LLC. View Insider Buying and Selling for Charles River Laboratories International.
How do I buy Charles River Laboratories International stock?
Shares of Charles River Laboratories International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Charles River Laboratories International's stock price today?
MarketBeat Community Rating for Charles River Laboratories International (NYSE CRL)MarketBeat's community ratings are surveys of what our community members think about Charles River Laboratories International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Charles River Laboratories International stock can currently be purchased for approximately $114.91.
Consensus Ratings for Charles River Laboratories International (NYSE:CRL) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||5 Hold Ratings, 4 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.44)|
|Consensus Price Target: ||$103.17 (10.22% downside)|Consensus Price Target History for Charles River Laboratories International (NYSE:CRL)
Analysts' Ratings History for Charles River Laboratories International (NYSE:CRL)
(Data available from 10/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/16/2017||Credit Suisse Group||Reiterated Rating||Neutral||$95.00 -> $112.00||N/A|
|10/9/2017||Jefferies Group LLC||Boost Price Target||Buy||$120.00 -> $130.00||N/A|
|9/19/2017||Royal Bank Of Canada||Initiated Coverage||Sector Perform -> Sector Perform||$110.00||Medium|
|9/1/2017||Robert W. Baird||Reiterated Rating||Buy||$114.00||Low|
|7/19/2017||Barclays PLC||Reiterated Rating||Hold||$102.00||Low|
|6/28/2017||Citigroup Inc.||Reiterated Rating||Neutral||$91.00 -> $104.00||Low|
|1/4/2017||Evercore ISI||Upgrade||Hold -> Buy||$86.50||N/A|
|12/16/2016||Goldman Sachs Group, Inc. (The)||Upgrade||Sell -> Neutral||$75.00 -> $77.00||N/A|
|11/18/2016||Bank of America Corporation||Set Price Target||Buy||$93.00||N/A|
|2/11/2016||Deutsche Bank AG||Reiterated Rating||Hold||$85.00 -> $82.00||N/A|
|1/7/2016||Wells Fargo & Company||Upgrade||Market Perform -> Outperform||N/A|
Earnings History for Charles River Laboratories International (NYSE:CRL)Earnings History by Quarter for Charles River Laboratories International (NYSE CRL)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/9/2017||Q2 2017||$1.22||$1.29||$458.25 million||$469.13 million||View||Listen|
|5/10/2017||Q1 2017||$1.14||$1.29||$437.04 million||$445.80 million||View||N/A|
|2/14/2017||Q416||$1.11||$1.21||$441.64 million||$466.80 million||View||Listen|
|11/2/2016||Q316||$1.13||$1.18||$291.20 million||$425.70 million||View||Listen|
|8/3/2016||Q216||$1.10||$1.20||$425.05 million||$434.10 million||View||Listen|
|5/4/2016||Q116||$0.90||$0.98||$354.92 million||$354.90 million||View||Listen|
|2/10/2016||Q415||$0.94||$1.00||$349.20 million||$353.90 million||View||Listen|
|11/4/2015||Q315||$0.94||$1.03||$340.09 million||$349.50 million||View||Listen|
|7/30/2015||Q215||$0.97||$0.96||$338.30 million||$339.60 million||View||Listen|
|4/29/2015||Q115||$0.82||$0.79||$324.00 million||$320.40 million||View||Listen|
|2/10/2015||Q414||$0.71||$0.81||$318.73 million||$329.50 million||View||Listen|
|10/29/2014||Q314||$0.80||$0.86||$326.70 million||$327.60 million||View||Listen|
|8/6/2014||Q214||$0.82||$0.97||$327.96 million||$341.18 million||View||Listen|
|4/30/2014||Q114||$0.74||$0.82||$302.08 million||$299.40 million||View||Listen|
|2/12/2014||Q413||$0.68||$0.73||$289.56 million||$289.20 million||View||Listen|
|10/30/2013||Q313||$0.70||$0.79||$290.28 million||$292.10 million||View||Listen|
|7/31/2013||Q2 2013||$0.71||$0.73||$293.77 million||$294.40 million||View||Listen|
|5/1/2013||Q1 2013||$0.71||$0.69||$294.53 million||$291.20 million||View||Listen|
|2/13/2013||Q4 2012||$0.60||$0.64||$280.81 million||$280.10 million||View||Listen|
Earnings Estimates for Charles River Laboratories International (NYSE:CRL)
2017 EPS Consensus Estimate: $4.89
2018 EPS Consensus Estimate: $5.77
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Charles River Laboratories International (NYSE:CRL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Charles River Laboratories International (NYSE:CRL)
Insider Ownership Percentage: 2.20%Insider Trades by Quarter for Charles River Laboratories International (NYSE:CRL)
Institutional Ownership Percentage: 97.22%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/5/2017||Davide Molho||Insider||Sell||6,165||$110.00||$678,150.00|| |
|9/5/2017||Davide Molho||Insider||Sell||5,982||$107.55||$643,364.10|| |
|8/17/2017||William D Barbo||Insider||Sell||4,000||$99.91||$399,640.00|| |
|8/14/2017||David Ross Smith||Insider||Sell||2,552||$67.10||$171,239.20|| |
|7/17/2017||George Massaro||Director||Sell||3,830||$100.81||$386,102.30|| |
|7/10/2017||James C Foster||Chairman||Sell||9,516||$98.92||$941,322.72|| |
|6/22/2017||Davide Molho||Insider||Sell||10,948||$100.00||$1,094,800.00|| |
|6/22/2017||James C Foster||Chairman||Sell||43,154||$100.00||$4,315,400.00|| |
|6/8/2017||David Ross Smith||Insider||Sell||945||$95.00||$89,775.00|| |
|5/26/2017||Davide Molho||Insider||Sell||10,976||$92.84||$1,019,011.84|| |
|5/12/2017||George Massaro||Director||Sell||1,130||$88.30||$99,779.00|| |
|3/16/2017||Davide Molho||Insider||Sell||11,717||$90.00||$1,054,530.00|| |
|3/10/2017||David P Johst||Insider||Sell||34,593||$89.06||$3,080,852.58|| |
|3/6/2017||William D Barbo||Insider||Sell||1,900||$87.90||$167,010.00|| |
|3/3/2017||David Ross Smith||EVP||Sell||3,890||$88.12||$342,786.80|| |
|3/1/2017||Robert J Bertolini||Director||Sell||5,255||$87.53||$459,970.15|| |
|2/28/2017||James C Foster||Chairman||Sell||4,910||$87.09||$427,611.90|| |
|2/22/2017||James C Foster||Chairman||Sell||9,717||$87.64||$851,597.88|| |
|1/30/2017||David P Johst||Insider||Sell||13,950||$78.00||$1,088,100.00|| |
|12/2/2016||Stephen D Chubb||Director||Sell||4,564||$71.57||$326,645.48|| |
|11/28/2016||C Richard Reese||Director||Sell||4,539||$71.93||$326,490.27|| |
|8/30/2016||Davide Molho||Insider||Sell||7,877||$84.10||$662,455.70|| |
|8/5/2016||James C Foster||Chairman||Sell||18,351||$85.63||$1,571,396.13|| |
|7/29/2016||Richard F Wallman||Director||Sell||7,740||$88.00||$681,120.00|| |
|7/1/2016||George Massaro||Director||Sell||3,740||$83.09||$310,756.60|| |
|5/24/2016||John J Crowley||CAO||Sell||1,913||$85.00||$162,605.00|| |
|5/13/2016||Richard F Wallman||Director||Sell||1,970||$82.32||$162,170.40|| |
|5/10/2016||Richard F Wallman||Director||Sell||11,990||$84.00||$1,007,160.00|| |
|5/9/2016||George Massaro||Director||Sell||985||$82.17||$80,937.45|| |
|5/6/2016||Richard F Wallman||Director||Sell||2,720||$81.00||$220,320.00|| |
|4/6/2016||Davide Molho||VP||Sell||30,667||$80.00||$2,453,360.00|| |
|3/2/2016||Nancy Gillett||VP||Sell||7,015||$75.00||$526,125.00|| |
|2/29/2016||Nancy Gillett||VP||Sell||3,646||$73.50||$267,981.00|| |
|2/25/2016||David P Johst||VP||Sell||34,075||$73.02||$2,488,156.50|| |
|2/24/2016||James C Foster||CEO||Sell||3,873||$70.40||$272,659.20|| |
|2/23/2016||George M Milne Jr||Director||Sell||10,440||$73.02||$762,328.80|| |
|2/22/2016||James C Foster||CEO||Sell||9,831||$73.12||$718,842.72|| |
|2/12/2016||C Richard Reese||Director||Sell||4,228||$71.48||$302,217.44|| |
|2/12/2016||Nancy Gillett||VP||Sell||6,750||$71.90||$485,325.00|| |
|2/1/2016||Stephen D Chubb||Director||Sell||2,000||$74.76||$149,520.00|| |
|12/17/2015||George Massaro||Director||Sell||7,740||$80.00||$619,200.00|| |
|12/17/2015||Thomas F. Ackerman||insider||Sell||10,000||$80.00||$800,000.00|| |
|11/19/2015||Thomas F. Ackerman||insider||Sell||10,000||$75.00||$750,000.00|| |
|11/4/2015||Thomas F. Ackerman||insider||Sell||21,612||$70.01||$1,513,056.12|| |
|11/2/2015||Stephen D Chubb||Director||Sell||2,000||$66.57||$133,140.00|| |
|8/17/2015||Thomas F Ackerman||Insider||Sell||5,000||$75.53||$377,650.00|| |
|5/15/2015||Thomas F Ackerman||CFO||Sell||3,900||$70.51||$274,989.00|| |
|5/7/2015||George Massaro||Director||Sell||1,360||$70.21||$95,485.60|| |
|3/3/2015||Stephen D Chubb||Director||Sell||2,000||$75.52||$151,040.00|| |
|3/2/2015||Deborah Turner Kochevar||Director||Sell||2,600||$76.59||$199,134.00|| |
|3/2/2015||James C Foster||CEO||Sell||2,036||$76.93||$156,629.48|| |
|3/2/2015||Nancy Gillett||VP||Sell||4,379||$76.72||$335,956.88|| |
|2/27/2015||Nancy Gillett||VP||Sell||2,772||$76.95||$213,305.40|| |
|2/25/2015||James C Foster||CEO||Sell||4,621||$75.96||$351,011.16|| |
|2/25/2015||Nancy Gillett||VP||Sell||5,015||$76.12||$381,741.80|| |
|2/24/2015||James C Foster||CEO||Sell||4,800||$75.70||$363,360.00|| |
|2/24/2015||Jorg Geller||VP||Sell||12,061||$76.17||$918,686.37|| |
|2/23/2015||James C Foster||CEO||Sell||8,423||$76.56||$644,864.88|| |
|2/23/2015||Jorg Geller||VP||Sell||7,041||$76.59||$539,270.19|| |
|2/20/2015||George M Milne Jr||Director||Sell||6,000||$75.87||$455,220.00|| |
|2/19/2015||James C Foster||CEO||Sell||9,671||$75.00||$725,325.00|| |
|2/18/2015||Stephen D Chubb||Director||Sell||5,011||$73.97||$370,663.67|| |
|2/17/2015||Jorg Geller||VP||Sell||14,430||$73.54||$1,061,182.20|| |
|2/17/2015||Thomas F Ackerman||CFO||Sell||4,400||$73.50||$323,400.00|| |
|2/13/2015||Davide Molho||VP||Sell||19,075||$74.00||$1,411,550.00|| |
|2/12/2015||Jorg Geller||VP||Sell||8,458||$73.68||$623,185.44|| |
|1/26/2015||Thomas F Ackerman||CFO||Sell||10,000||$70.00||$700,000.00|| |
|1/8/2015||David P Johst||VP||Sell||4,737||$67.00||$317,379.00|| |
|1/7/2015||David P Johst||VP||Sell||26,100||$65.00||$1,696,500.00|| |
|12/1/2014||Stephen D Chubb||Director||Sell||2,000||$64.44||$128,880.00|| |
|11/28/2014||David P Johst||VP||Sell||6,982||$65.34||$456,203.88|| |
|11/17/2014||Thomas F Ackerman||CFO||Sell||10,000||$63.70||$637,000.00|| |
|11/14/2014||Jorg Geller||VP||Sell||5,610||$63.57||$356,627.70|| |
|11/6/2014||C Richard Reese||Director||Sell||5,849||$63.39||$370,768.11|| |
|11/4/2014||John J Crowley||CAO||Sell||1,000||$64.00||$64,000.00|| |
|11/3/2014||Davide Molho||VP||Sell||16,402||$64.54||$1,058,585.08|| |
|11/3/2014||George Massaro||Director||Sell||16,710||$65.00||$1,086,150.00|| |
|11/3/2014||Thomas F Ackerman||CFO||Sell||36,100||$65.00||$2,346,500.00|| |
|10/30/2014||Nancy Gillett||VP||Sell||1,069||$65.00||$69,485.00|| |
|10/28/2014||David P Johst||VP||Sell||74,780||$64.00||$4,785,920.00|| |
|10/3/2014||James C Foster||CEO||Sell||136,647||$62.00||$8,472,114.00|| |
|9/29/2014||Thomas F Ackerman||CFO||Sell||5,000||$60.00||$300,000.00|| |
|9/4/2014||Davide Molho||VP||Sell||4,900||$61.34||$300,566.00|| |
|9/2/2014||Stephen D Chubb||Director||Sell||2,000||$59.18||$118,360.00|| |
|8/26/2014||George Massaro||Director||Sell||10,440||$60.00||$626,400.00|| |
|8/18/2014||Thomas F Ackerman||CFO||Sell||23,156||$59.25||$1,371,993.00|| |
|8/12/2014||Richard F Wallman||Director||Sell||3,240||$58.20||$188,568.00|| |
|6/2/2014||Stephen D Chubb||Director||Sell||2,000||$52.93||$105,860.00|| |
|5/22/2014||Deborah Turner Kochevar||Director||Sell||3,100||$53.30||$165,230.00|| |
|5/8/2014||George Massaro||Director||Sell||1,620||$52.70||$85,374.00|| |
|5/5/2014||Thomas Ackerman||CFO||Sell||5,430||$50.76||$275,626.80|| |
|3/7/2014||Nancy Gillett||VP||Sell||10,110||$58.36||$590,019.60|| |
|3/4/2014||Nancy Gillett||VP||Sell||13,650||$58.98||$805,077.00|| |
|3/3/2014||Stephen Chubb||Director||Sell||2,000||$58.70||$117,400.00|| |
|2/28/2014||Jorg Geller||VP||Sell||7,486||$59.41||$444,743.26|| |
|2/27/2014||Nancy Gillett||VP||Sell||4,000||$60.00||$240,000.00|| |
|2/25/2014||Jorg Geller||VP||Sell||3,188||$58.49||$186,466.12|| |
|2/20/2014||Nancy Gillett||VP||Sell||4,000||$58.96||$235,840.00|| |
|2/19/2014||Stephen Chubb||Director||Sell||5,198||$58.35||$303,303.30|| |
|2/18/2014||Thomas Ackerman||CFO||Sell||14,000||$58.05||$812,700.00|| |
|1/13/2014||David Johst||VP||Sell||19,750||$58.00||$1,145,500.00|| |
|1/7/2014||George Massaro||Director||Sell||5,750||$54.00||$310,500.00|| |
|12/20/2013||Thomas Ackerman||CFO||Sell||5,000||$52.72||$263,600.00|| |
|12/4/2013||Jorg Geller||VP||Sell||7,200||$51.93||$373,896.00|| |
|12/2/2013||Stephen Chubb||Director||Sell||2,000||$51.92||$103,840.00|| |
|9/16/2013||George Massaro||Director||Sell||5,958||$47.38||$282,290.04|| |
|9/9/2013||James C Foster||CEO||Sell||174,479||$47.00||$8,200,513.00|| |
|9/4/2013||Thomas F Ackerman||CFO||Sell||6,100||$46.13||$281,393.00|| |
|9/3/2013||Stephen Chubb||Director||Sell||2,000||$46.49||$92,980.00|| |
|8/29/2013||James Foster||CEO||Sell||40,983||$47.00||$1,926,201.00|| |
|8/22/2013||Davide Molho||VP||Sell||6,500||$47.93||$311,545.00|| |
|8/20/2013||Stephen Chubb||Director||Sell||4,000||$47.46||$189,840.00|| |
|8/5/2013||Jorg Geller||VP||Sell||3,025||$46.38||$140,299.50|| |
|8/5/2013||Richard Wallman||Director||Sell||1,500||$45.95||$68,925.00|| |
|8/2/2013||Davide Molho||VP||Sell||4,100||$45.89||$188,149.00|| |
|8/2/2013||Deborah Turner Kochevar||Director||Sell||4,447||$46.02||$204,650.94|| |
|8/2/2013||Thomas Ackerman||CFO||Sell||26,250||$46.03||$1,208,287.50|| |
|6/3/2013||Thomas F Ackerman||CFO||Sell||4,000||$42.40||$169,600.00|| |
|5/14/2013||James C Foster||CEO||Sell||113,810||$45.00||$5,121,450.00|| |
|5/10/2013||George Massaro||Director||Sell||2,020||$44.09||$89,061.80|| |
|3/13/2013||David P Johst||VP||Sell||17,038||$45.00||$766,710.00|| |
Headline Trends for Charles River Laboratories International (NYSE:CRL)
Latest Headlines for Charles River Laboratories International (NYSE:CRL)
Loading headlines, please wait.
Charles River Laboratories International (CRL) Chart for Tuesday, October, 24, 2017